Skip to main content
NATR
NASDAQ Life Sciences

NATURES SUNSHINE PRODUCTS INC Reports Doubled Net Income and EPS, Acquires Full Ownership of China JVs, and Expands Share Repurchase Program

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
9
Price
$26.3
Mkt Cap
$438.789M
52W Low
$11.01
52W High
$28.14
Market data snapshot near publication time

summarizeSummary

NATURES SUNSHINE PRODUCTS INC reported strong full-year 2025 financial results, with net sales up 5.7%, net income more than doubling, and EPS significantly increasing. The company also completed the acquisition of full ownership in its China joint ventures and expanded its share repurchase program.


check_boxKey Events

  • Strong Financial Performance

    Net sales increased 5.7% to $480.1 million for the year ended December 31, 2025, compared to $454.4 million in 2024. Net income more than doubled to $20.5 million from $7.9 million, and basic earnings per share rose to $1.08 from $0.41.

  • Acquired Full Ownership of China Joint Ventures

    The company completed the purchase of Fosun Industrial's remaining interests in Nature's Sunshine Hong Kong Limited and Shanghai Nature's Sunshine Health Products Co., Ltd. for a total consideration of $7.0 million ($6.0 million cash paid at closing and $1.0 million deferred), gaining 100% control of these key Asian operations.

  • Expanded Share Repurchase Program

    The share repurchase program was amended on May 6, 2025, to authorize an additional $25.0 million in common share repurchases. The company repurchased 1,260,000 shares for $16.3 million during 2025, with $17.4 million remaining available under the program.

  • Improved Effective Tax Rate

    The effective tax rate significantly decreased to 31.4% in 2025 from 57.2% in 2024, primarily due to the expiration of foreign tax credits in the prior period and reduced valuation allowances.


auto_awesomeAnalysis

NATURES SUNSHINE PRODUCTS INC delivered exceptionally strong financial results for fiscal year 2025, with significant growth across key metrics. The more than doubling of net income and EPS indicates robust operational performance and improved profitability. The strategic acquisition of full ownership in its China joint ventures is a material development, providing greater control and potential for growth in critical Asian markets. Furthermore, the expansion of the share repurchase program and substantial repurchases demonstrate management's confidence in the company's valuation and commitment to returning capital to shareholders. The improved effective tax rate also contributes positively to the bottom line. These factors collectively present a very positive outlook for the company.

At the time of this filing, NATR was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $438.8M. The 52-week trading range was $11.01 to $28.14. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed NATR - Latest Insights

NATR
Apr 20, 2026, 5:28 PM EDT
Filing Type: DEFA14A
Importance Score:
8
NATR
Mar 27, 2026, 5:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
NATR
Mar 17, 2026, 5:11 PM EDT
Filing Type: 4
Importance Score:
7
NATR
Mar 17, 2026, 5:10 PM EDT
Filing Type: 4
Importance Score:
7
NATR
Mar 10, 2026, 5:10 PM EDT
Filing Type: 10-K
Importance Score:
9
NATR
Mar 10, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8